The fund primarily allocates its capital to the common stock of companies within the broad healthcare sector, specifically targeting businesses engaged in pharmaceuticals, biotechnology, healthcare services, health technology, medical technology, and life sciences. The adviser seeks out industry leaders in these areas whose potential for future growth, both in scale and longevity, is believed to be underestimated by the market. Under typical market conditions, a minimum of 80% of the fund's assets will be invested in the equity securities of such healthcare-related enterprises.